Spexis AG (Spexis AG) Short-Term Debt : $1.96 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Spexis AG Short-Term Debt?

Spexis AG's Short-Term Debt for the quarter that ended in Dec. 2023 was $1.96 Mil.

Spexis AG's quarterly Short-Term Debt declined from Dec. 2022 ($0.69 Mil) to Jun. 2023 ($0.34 Mil) but then increased from Jun. 2023 ($0.34 Mil) to Dec. 2023 ($1.96 Mil).

Spexis AG's annual Short-Term Debt declined from Dec. 2021 ($1.67 Mil) to Dec. 2022 ($0.69 Mil) but then increased from Dec. 2022 ($0.69 Mil) to Dec. 2023 ($1.96 Mil).

Spexis AG Short-Term Debt Historical Data

The historical data trend for Spexis AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Short-Term Debt Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

0.26

3.71

1.67

0.69

1.96

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial													1.67	1.01	0.69	0.34	1.96

Spexis AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Spexis AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Spexis AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (Spexis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (OTCPK:PPHOF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

SPEXz:UK SPEX:Switzerland

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (Spexis AG) Headlines

No Headlines